First CBD Oil Shop In Fall River Ready For Opening Day

“FALL RIVER — After losing her daughter three years ago, Laura Eaton has found the motivation not only to go on, but to live well, and to start her own business helping people discover their own journey to wellness.

Janelle “Nelly” Eaton became locally famous for her courageous and graceful battle with cancer that ended on Nov. 21, 2015, at the age of 17. Since that time, her mom and family have continued the Nelly Strong Foundation to promote public education and awareness about natural healing for those with chronic and critical illnesses.

Troy City Wellness, a business specializing in CBD oil and other natural wellness products, will open on March 2 at 222 E. Main St. It is the first CBD oil shop in the city, though some others do sell CBD products.

Cannabidiol, or CBD, is a compound of the cannabis plant that alternative medicine practitioners, and some traditional health care professionals, believe may help people find relief from anxiety, pain, epilepsy, stress, skin conditions and more.

It is a full-spectrum organic product that is non-psychoactive, meaning it does not produce a “high.”

Eaton said she’s had an interest in CBD oil years before it became mainstream when she saw it help her daughter deal with the effects of her disease.

Continue Reading at South Coast Today

CBD for cancer: Everything You Need To Know

”Cannabidiol, or CBD, is one of many cannabinoids in the cannabis plant gaining popularity in the world of natural medicine because it appears to offer the body many benefits. While there is some debate around the topic, some people suggest using CBD in the treatment of cancer.

Although it is too early to make any claims about CBD for cancer treatment, this compound may help manage symptoms that occur due to this disease or its treatment.

It is important to note that CBD is not the same as tetrahydrocannabinol (THC), which is an active cannabinoid in cannabis that causes a “high” when a person smokes or ingests it. Researchers are also looking at the possibility of using CBD for treating anxiety and chronic pain.

Some people wonder about using cannabis or CBD to prevent cancer. The National Cancer Institute (NCI) reviewed numerous studies regarding the link between cannabis and cancer and found that the research has mixed results.

An older study of 64,855 men from the United States found that cannabis use did not increase the risk of tobacco-related cancers. However, this same study also found that male cannabis users who never smoked tobacco had an increased risk of prostate cancer.

On the other hand, the authors of a 2015 study found a promising relationship between cannabis and bladder cancer. After adjusting for several factors, they found that that cannabis users had a 45-percent lower risk of developing bladder cancer.

However, ingesting CBD extract does not expose the body to the same carcinogens as smoking marijuana. More long-term studies in humans are necessary to determine what role, if any, CBD has to play in the prevention of cancer.

In 2016, researchers noted that the use of cannabinoids shows promise in the fight against cancer. The authors found that cannabinoids seem to inhibit the growth of many different types of tumor cell in both test tubes and animal models.

Continue Reading at Medical News Today

How Minnesota Can Fix Its Medical Marijuana Market

“New patients are leaving the program in droves, turning to the black market or prescription opioids because they cannot afford the processed pills and oils that are legal. Growers are losing millions because of a strict tax structure written into the law.

Lawmakers can fix this, but they might have to look beyond their home state for solutions. A slew of proposals at the State Capitol could save the manufacturers money and help them lower prices. Patients say they do not go far enough.

Minnesota’s medical cannabis program is widely seen as one of the most restrictive in the country; the costly drugs are not insured and only patients with one of 13 severe conditions can use them.

Is there a commitment to shed that reputation?

Minnesota Gov. Tim Walz told the Pioneer Press that he would support legislative changes to the program, which he said is “very cumbersome” and “doesn’t work.”

“It felt like they did the bare minimum they could do just to kind of limp over,” Walz said, referring to the compromise that lawmakers and former Gov. Mark Dayton struck to legalize medical marijuana in 2014. “Now we’re stuck with a very minimal medicinal cannabis (program) that really is too expensive.”

The average patient shelled out $300 when he or she went to a dispensary, according to the Pennsylvania Department of Health. In contrast, most patients who spoke to the Pioneer Press say they spend between $200 and $500 per month.

In August, Pennsylvania officials made a major change to the program. They legalized the marijuana plant for medicinal use, and prices began to drop. By Feb. 1, the average cost per patient on a trip to a dispensary had fallen to $130.

Read more at Twin Cities

Arecanut Gets Its First GI Tag For ‘Sirsi Supari’

“For the first time in the arecanut sector, ‘Sirsi Supari’ grown in Uttara Kannada has received the Geographic Indication (GI) tag. It is cultivated in Yellapura, Siddapura and Sirsi taluks.

Totgars’ Cooperative Sale Society Ltd., Sirsi, is the registered proprietor of the GI.

The Registrar of Geographical Indications, under the Union government, Chennai issued the certificate to the society on March 4, 2019. Its GI number is 464.

This particular variety has a unique taste due to differences in chemical composition. The total average flavonoids content in it is around 90 whereas in others it is around 80.

The total carbohydrates in ‘Sirsi Supari’ are 23% to 26%, total arecoline is 0.11% to 0.13%, total tannin content is 14.5% to 17.5%.

Ravish Hegde, General Manager of the cooperative, told The Hindu that the process of obtaining the tag had begun in 2013. It took about six years to get it owing to scientific research proof to be submitted to prove its uniqueness.

Read the full article at The Hindu

Home Grown Marijuana in New York: Will it be legal?

To David R. Clifford of Auburn, it just makes sense: If marijuana becomes legal for adult recreational use in New York, he says, consumers should be able to grow their own.

“I can grow my own tomatoes or herbs,” he said. “If I’m a beer drinker, I can grow my own hops and make some home brew. So why not let me grow my own cannabis?”

It may not happen. While New York lawmakers are considering legalizing marijuana for recreational use, the proposal offered by Gov. Andrew Cuomo earlier this year does not allow growing at home for non-medical use. Recreational users would have to buy their weed from a state-licensed retail outlet.

Versions of the legalization plans introduced in both the Assembly and Senate do appear to authorize up to six plants to be cultivated for private use. Those bills make no reference to limiting it for medical use.

Home-grown weed is just one of many details still to be worked out on New York’s path to legal recreational marijuana. Cuomo is hoping to have a law approved by April 1, in time for the upcoming state budget. Some lawmakers, including Assembly Speaker Carl Heastie, think that timetable may be too fast.

At the heart of the recreational marijuana proposals are provisions allowing those over 21 to possess limited amounts of weed for personal use. The plans also deal with setting up retail outlets, authorizing taxes and addressing social issues, such as sealing the criminal records of those convicted of past marijuana offense.

Continue Reading at Syracuse.com

Legal Weed in Illinois is Closer Than You Think

 

ILLINOIS- The landslide victory of J.B Pritzker in the November midterms may prove to be the catalyst for legal recreational Cannabis in Illinois.

State Rep. Kelly Cassidy, D-Chicago said one of the obstacles for Illinois to get it legalized had been Gov. Bruce Rauner, who opposed the move.

With Michigan leading the way for recreational marijuana in the midwest many Illinois legislators seem anxious to make Illinois next.

A 2016 Gallup poll found that 60% of Americans support full legalization, a drastic increase from 36% in 2005. Voters seem keen on the idea.

According to dea.gov:

“Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse.”

States wouldn’t have to spend so much money arresting, trying and imprisoning buyers and sellers as well as the huge tax revenue increases from marijuana sales.

According to potguide.com there are 55 medical marijuana dispensaries in Illinois. Several companies are banking on marijuana in Illinois, and they are poised to make moves once recreational is legalized.

WQAD8

Can LSD and Magic Mushrooms Help Win Wars?

“Sanctioned psychedelic drug use as a medical or psychological treatment method is gaining ground as part of today’s hallucinogenic renaissance.

Recent scientific studies approved by the Food and Drug Administration have yielded positive cognitive results when administering “microdoses” of the drugs lysergic acid diethylamide, or LSD, and psilocybin, the alkaloid in hallucinogenic mushrooms.

But could this new wave of unorthodox treatment ever find its way into the ranks of the military? According to an article by Marine Maj. Emre Albayrak that was published in the February issue of the Marine Corps Gazette, it certainly should.

Microdosing, which refers to administering a minuscule quantity of the drug in order to avoid hallucinations or debilitating effects in the patient, is already being used by “scientists, Silicon Valley executives, biologists, biohackers, and others” to achieve a mental edge, Albayrak writes.

Administering in such doses has the potential to “significantly heighten alertness, creativity, and problem-solving.”

But an inability to process “superhuman” amounts of information in a community in which “one percent gains provide significant advantages” on the battlefield necessitates a better solution, Albayrak suggests.

Enter LSD and magic mushrooms.

“Like most hallucinogens, LSD mimics the effects of serotonin (a mood regulator),” the author says and activates enhanced mental acuity in the areas of learning and memory.

Additionally, the drug commonly referred to as “acid” can decrease blood circulation to the part of the brain that instigates periods of mind wandering.

Read the full article at Marine Times

UN Opium Survey distorts the Facts, Says Think Tank

“YANGON — The United Nations Office on Drugs and Crime has been accused of “distorting realities of the situation on the ground” in its latest Myanmar opium survey, in a report by the Transnational Institute, a think tank based in Amsterdam.

In the report, A distortion of reality: Drugs, conflict and the UNODC’s 2018 Myanmar Opium Survey, released on March 4, TNI takes issue with accusations the UN agency makes about armed ethnic groups.

They include the Kachin Independence Organisation, a political wing of the Kachin Independence Army, which issued an open letter to the UNODC on February 15 that rejected the survey’s findings and demanded a retraction.

It says the two main opium-growing areas in Kachin are at Sadung in Waingmaw Township bordering China, where cultivation takes place in areas under the nominal control of two Border Guard Force groups under Tatmadaw command, and in the tiger reserve in Tanai Township, which is also under ostensible government control.

TNI said its sources had confirmed that there was currently no substantial opium cultivation in areas controlled by the KIO, which has for several years carried out a strict anti-drugs campaign, including eradicating opium fields.

International organizations such as the UNODC need to be aware that inaccurate reporting is a high-risk activity that could have a negative effect on efforts to promote peace and political reform in Myanmar, the think tank said.

The links between drugs and conflict were a vital issue that needed to be discussed, transparently and openly, during political negotiations to achieve peace, it said. “This is a matter of concern for all Myanmar’s peoples.”

Continue Reading at Frontier Myanmar

CBD Oil and Pets: Can It Relieve Anxiety And Pain?

“CBD oil is a non-intoxicating hemp extract that many pet owners are after to treat a variety of ailments. But veterinarians say there are some things to consider first.

Pain, arthritis and seizures are just some of the health problems that have more and more people turning to CBD for their pets.

North Carolina is one of 47 states where CBD is legal for human use. Physicians in those states can recommend CBD to their patients, and consumers can purchase it at retail locations.

Cannabis for pets is largely unregulated, so it’s difficult to know which CBD products are formulated responsibly.

Consumer Reports recommends looking for the seal from the National Animal Supplement Council, which can help identify quality products.

WRAL.com

Is Auxly Cannabis a Buy?

Momentum continues to pick up for the marijuana industry. But not every marijuana stock is prospering.

Auxly Cannabis  (NASDAQOTH:CBWTF) lost more than half its value in 2018, making it one of the 10 worst-performing marijuana stocks of the year. So far in 2019, the stock is down close to 20% while the shares of many of its peers are soaring. But is Auxly now such a bargain that it’s a great pick for long-term investors to buy?

THE GOOD

Auxly’s share price hasn’t reflected the tremendous potential the company has. But that potential exists nonetheless.

Estimates vary about just how big the global marijuana market could be. However, projections of $100 billion or more within the next decade don’t appear to be unrealistic. Auxly itself estimates that the total market could be close to $50 billion by 2024. The company doesn’t have to be a big player in a market of that size to be enormously successful.

Auxly offers one key advantage to investors that most marijuana stocks don’t: diversification across the cannabis supply chain. The company’s revenue streaming partnerships, joint ventures, equity investments, and subsidiaries make Auxly a player in the upstream cultivation, midstream extraction and processing, and downstream distribution and sales segments of the cannabis industry.

THE BAD

Despite its impressive efforts in wheeling and dealing, Auxly has yet to make even a cent of profit. In the third quarter of 2018, the company posted a loss totaling nearly 4.6 million Canadian dollars, or around $3.5 million.

Auxly’s problem isn’t just that it’s spending a lot of money (which it is); the company simply isn’t making much revenue, either. In Q3, Auxly’s revenue totaled a measly CA$512,000 — roughly $385,000.

The primary issue for Auxly is that most of its upstream partners are still ramping up their production capacity. They can’t sell what they can’t produce.

Read the full article at The Motley Fool

Could Mushrooms Be The Next Drug To Be Decriminalised?

“Marijuana and magic mushrooms. One’s a plant, one’s a fungi, both are illegal – for now.

But psychedelic drug reform is already happening in the US. The city of Denver, which has already legalized recreational cannabis, is preparing to vote on whether to decriminalize magic mushrooms in May.

With New Zealand moving towards a referendum on our cannabis laws, News-hub spoke to Victoria University drug use expert Dr Fiona Hutton about whether or not we need to take a look at our laws on mushrooms.

Magic mushrooms (or shrooms) contain psilocybin, which is converted in the body to the psychedelic substance psilocin. They’re classified as Class A, meaning they come with the strongest penalties if you get caught with them.

Possession is a maximum of six months in prison – while the maximum penalty for supply is life in prison.

In medical trials, patients reported improvements in anxiety and depression. Other studies found psilocybin could help users kick their drug, alcohol, and nicotine addictions.

In the US, drug researchers, including Johns Hopkins University researcher Dr Matthew Johnson, said they were worried about the risk of bad trips and how people with psychotic disorders could be affected.

According to the 2017 annual Global Drug Survey, which relies on self-reported drug use, the rate of users who needed emergency medical care after using mushrooms was three times lower that of cannabis.

And research by UK drug expert Prof Nutt found that mushrooms were statistically the least dangerous out of 20 drugs, including alcohol, tobacco, cannabis and LSD.

Read the full article at Newshub

Denver Should Legalize Magic Mushrooms

“The decriminalization of magic (psilocybin) mushrooms is going to be on the ballot in Denver in May, and voters should definitely go for it.

On February 1, the Denver Elections Division certified a petition from decriminalization activists, noting that it had received enough signatures for voters to decide on the issue in the municipal election. The measure would decriminalize the use of psilocybin — or “magic” — mushrooms within city limits.

It’s important to note that the measure would not legalize the drug, but simply make stopping possession of it a low priority for police, prohibiting the city and county from using any of its resources to punish people ages 21 and older for possessing the drug. The drug would still, of course, be considered illegal on the federal level.

Although mushrooms are a drug that may carry a lot of stigma, voters would be right to pass this measure in May. In fact, speaking generally, I would argue that drug decriminalization is always the right choice. After all, we are supposed to be a country that was founded on the principles of freedom and individual liberty, and locking people up for what they choose to put in their own bodies certainly seems opposite to that philosophy.

Another study suggests that mushrooms are also helpful for the mental health of those who are suffering with life-threatening illnesses. In 2016, a Johns Hopkins study reported that cancer patients who had received psilocybin experienced an average 78 percent reduction in depression and an 83 percent reduction in anxiety.

Read the full article at National Review

How Will Denver Change if it Decriminalizes Magic Mushrooms?

“The Mile-High City might be about to get a bit higher. In May, the citizens of Denver, Colorado, will vote on whether or not to decriminalize magic mushrooms, the colloquial name given to a group of mushroom species that contain the psychoactive compound psilocybin.

In the US, psilocybin is classified as a Schedule I drug, taking a place alongside heroin and ecstasy, ostensibly as one of the most dangerous drugs around. However, this classification doesn’t seem to jibe with the scientific consensus on magic mushrooms.

Psilocybin is typically not abused and is not addictive (in fact, some research has shown it to reduce addiction to other drugs). Furthermore, it does indeed have some medical purposes. Research has shown that its impact on depression, anxiety, and other psychological conditions is profound.

But Denverites aren’t talking about legalizing magic mushrooms purely for their medicinal properties; rather, they will be voting on whether or not to decriminalize the drug. First, decriminalization does not mean legalization—buying and selling the drug will still be illegal, but using and possessing it will simply not be prosecuted. Since this means the infrastructure to support its medical use won’t exist, we can assume that more Denverites will be using the drug recreationally.

If decriminalization and eventual legalization go ahead in Denver, what will this mean? Well, in addition to hallucinations, a distortion of time, and a sense of connectedness to the universe, magic mushrooms also have some more interesting long-term effects. First, some studies show that psilocybin usage can make people experience greater personal meaning, spiritual significance, and life satisfaction even six months after their initial dose.

Continue Reading at Big Think

Inside the Push to Legalize Magic Mushrooms for Depression and PTSD

“IT WASN’T. The former corporate executive from Colorado retired in 2006 after an MRI revealed his spine was riddled with a dozen tumors called hemangiomas, which later spread to his brain. Todd was told he would die before the end of 2008.

Somehow, Todd has survived—he credits medical marijuana, which he now uses daily—but he is still considered terminal. “It could be tomorrow. It could be five years from now,” he says in a call.

However, the 54-year-old spent the past decade plagued by a host of mental health problems, including PTSD and treatment-resistant depression. He was suicidal and tormented by violent night terrors. Nothing, not even massive doses of Xanax or Valium, could temper his panic attacks or end-of-life anxiety.

That was about a year ago. Todd began taking homegrown psilocybin, the highly illegal alkaloid in so-called magic mushrooms. Known for prompting profound hallucinations, psilocybin was placed in the restrictive Schedule I category in 1970, meaning the US government recognizes no medical use for the drug and says that it carries a high risk of abuse.

Todd says there have been clear benefits from psilocybin with few side effects. He hasn’t had a single PTSD episode since he began taking it. His depression evaporated. The mushrooms even help ease the pain—agony that feels like being “shot in the back”—from the nerve-crushing tumors in his spine and skull.

Indeed, magic mushrooms are having a therapeutic moment. In North America, at least four organizations, each with unique strategies, are working to expand access to psilocybin for anyone with mental health issues, dying or not. These groups hope to undo decades of psilocybin prohibition by removing criminal penalties for possession or cultivation, or by providing access to psilocybin in a therapist’s offices, or both.

Read more at Wired

The Failing Battle Against Drug Production in Colombia

”Despite several strategies to eradicate domestic cocaine production, Colombia continues to struggle with the massive amount of drugs that are cultivated and manufactured within its borders. Government control measures include the arrest of major drug lords and the dismantling of their cartels, as well as the prosecution of corrupt politicians and police officers involved in the drug trade.

Colombia is a world leader in cocaine cultivation and a major heroin supplier to the world. Coca leaves, the key ingredient in cocaine production, are grown in Colombia’s Andes Mountains. This area has been the focus of crop eradication for decades.

From 2000 to 2005, the United States appropriated about $4.3 billion for the Andean Counter-Drug Initiative, according to a report from the Congressional Research Service. The funds were targeted to eradicate the coca and opium poppy plants used to produce the illicit drugs.

The International Agency for Research on Cancer, a World Health Organization affiliate, found in 2015 that the aerial pesticide spray glyphosate (also known as Roundup) exposed Colombian farmers and villagers to a possible carcinogenic. Consequently, the Colombian government banned its use after it had been on the market for nearly two decades.

The next strategy was to send government workers into remote mountainous areas where farmers cultivate cocaine and heroin ingredients and offer them crop substitution as a new solution. The goal was to entice farmers to replace their illicit crops with legitimate ones, such as fruits and vegetables.

The goal of the peace treaty was to end the epidemic of violence and formulate a definitive solution to Colombia’s drug problem. As part of the deal, Bogota promised to provide health and education services along with potable water in rebel lands. FARC members were also granted amnesty for their crimes.

However, the Insight Crime Foundation, which tracks organized criminal groups, estimates that as many as 2,800 FARC members rejected these peace efforts. They rearmed themselves, demonstrating the ineffectiveness of the treaty.

Read more at In Homeland Security

8 Things Everyone Gets Wrong About CBD

“The past year has seen a surge of interest in marijuana’s CBD, a non-intoxicating cannabis compound with significant therapeutic properties. Numerous commercial start-ups and internet retailers have jumped on the CBD bandwagon, touting CBD derived from industrial hemp as the next big thing, a miracle oil that can shrink tumors, quell seizures, and ease chronic pain — without making people feel “stoned.” But along with a growing awareness of cannabidiol as a potential health aid, there has been a proliferation of misconceptions about CBD.

CBD is Medical. THC is recreational

Project CBD receives many inquiries from around the world and oftentimes people say they are seeking “CBD, the medical part” of the plant, “not THC, the recreational part” that gets you high. Actually, THC, “The High Causer,” has awesome therapeutic properties. Scientists at the Scripps Research Center in San Diego reported that THC inhibits an enzyme implicated in the formation of beta-amyloid plaque, the hallmark of Alzheimer’s-related dementia.

THC Is The Bad Cannabinoid. CBD is the good cannabinoid

The drug warrior’s strategic retreat: Give ground on CBD while continuing to demonize THC. Diehard marijuana prohibitionists are exploiting the good news about CBD to further stigmatize high-THC cannabis, casting tetrahydrocannabinol as the bad cannabinoid, whereas CBD is framed as the good cannabinoid. Why? Because CBD doesn’t make you high as THC does.

CBD Is Most Effective Without THC

THC and CBD are the power couple of cannabis compounds — they work best together. Scientific studies have established that CBD and THC interact synergistically to enhance each other’s therapeutic effects. British researchers have shown that CBD potentiates THC’s anti-inflammatory properties in an animal model of colitis.

Continue Reading at The Growth Shop

Scientists Find Psilocybin Microdosing Can Boost Cognitive Creativity

Recent research on LSD indicates the drug has potential to treat mental disorders and improve our understanding of human consciousness. Meanwhile, studies in recent years have explored the effects of psilocybin—the psychoactive compound occurring naturally in magic mushrooms—on quitting smoking; lowering violent crime; treating depression, anxiety, and post-traumatic stress disorder; and triggering spiritual epiphanies.

Now, an Oct. 25 study in Pharmacology—the official journal of the European Behavioral Pharmacology Society—adds to this growing body of knowledge. It examines another potential benefit of psilocybin. Researchers from Leiden University in The Netherlands studied the cognitive effects of micro-dosing psilocybin truffles (technically not mushrooms, but instead the hardened vegetative part of a fungus). They found that tiny doses can stimulate brain function and boost creativity without harming reasoning abilities.

Microdoses contain about 10% of the psychoactive components of a standard dose of psilocybin. The idea is to get the benefits but not the downsides of the drug, minimal effects that can stimulate thinking but not lead to extremes, like hallucinations.

For this study, the researchers tested the effects of about .035 grams of a psychoactive truffle on 36 subjects. (They later did a chemical composition analysis of the truffles to make sure psilocybin was evenly distributed throughout the truffles.) They investigated three types of thinking by presenting the subjects with different three tasks—developed by psychologists to test cognition—which was performed both before and after ingesting the drug. The scientists studied subjects’ convergent thought, which involves identifying a single solution for a single problem; their fluid intelligence, or reasoning and problem-solving; and their divergent thinking, the ability to recognize many solutions.

Read more at Quartz

The Problems with the UK’s Legalization of Medical Cannabis

Since last Thursday, medical cannabis has been legal in the UK. This means specialist doctors are now able to prescribe cannabis products for conditions where there is a proven medical benefit, potentially helping thousands of people suffering from severe forms of epilepsy, multiple sclerosis (MS), chronic pain, and nausea as a result of chemotherapy, among other ailments.

This landmark change in the law occurred after several stories came to light of sick children suffering under prohibition, including Billy Caldwell. The severely epileptic 12-year-old hit headlines earlier this year when the Home Office confiscated the Canadian-bought cannabis oil that made his condition manageable. Nationwide horror at the situation prompted Home Secretary Sajid Javid to order a review of the law, after which it was decided that cannabis should be changed from a Schedule 1 drug (no medical value) to a Schedule 2 (can be prescribed).

An MS Society statement said: “It’s likely that nothing will change in the short-term for the one in ten people who get relief from pain and muscle spasms by using medical cannabis. We’re calling for the interim guidance of prescribing medical cannabis to be urgently reviewed so that access to the treatment isn’t so restricted.”

Despite the limited scope laid out in the guidelines, Health Secretary Matt Hancock seemed to imply that doctors are being given a certain level of flexibility. He said: “Doctors need to use their clinical judgment, and having guidance in place helps. Ultimately, the need to treat a person and the responsibility for that falls on the shoulders of a doctor—that’s what they do.” Indeed, there will be no direct policy from a government that limits the conditions for which medical cannabis can be prescribed.

Read the full article at Vice

Report Says: More Women Are Using Marijuana During Pregnancy

Between 2002 and 2016, the percentage of pregnant women who reported smoking cigarettes while expecting fell significantly: from 17.5% to about 10%, according to a research letter published Monday in JAMA Pediatrics. Alcohol use also fell modestly during this period, from nearly 10% to about 8.5%. But cannabis use among pregnant women — while still relatively rare — is on the rise, increasing from almost 3% of pregnant women to almost 5%.

Those figures were based on responses to the National Survey of Drug Use and Health. About 12,000 pregnant women ages 18 to 44 responded to the survey between 2002 and 2016; roughly 3,500 of these women were in their first trimester of pregnancy, a critical time for fetal development.

Meanwhile, the decline in smoking cigarettes while pregnant corresponds with an overall decrease in the number of Americans who smoke. The percentage of smokers in the U.S. hit a new low recently, dropping from 45.1 million cigarette users in 2005 to 36.5 million, or about 15% of the population, in 2015. The researchers did find, however, that decreases in smoking were less pronounced among specific subgroups of pregnant women, including black women, women ages 26 to 44 and those who did not finish high school.

There is far less research on the health effects of marijuana, but in general, the CDC and other public health organizations have warned expectant mothers not to use the drug while pregnant, due to potential developmental harms for infants. Similar warnings exist for smoking cigarettes while pregnant.

Time

Cannabis Extract Relieves Chronic Pain Minus The High

In the wake of cannabis legalization in Canada, a team of scientists has delivered encouraging news for chronic pain sufferers by pinpointing the effective dose of marijuana plant extract cannabidiol for safe pain relief without the typical “high” or euphoria that THC produces. The findings of their study have been published in the journal PAIN.

Cannabis indica and sativa are the two main cannabis strains that produce the pharmacological principles known as tetrahydrocannabinol (THC) and cannabidiol (CBD). The team demonstrated that CBD does not act on the CB1 cannabinoid receptors like THC, but through the mechanism that binds specific receptors involved in anxiety (serotonin 5-HT1A) and pain (vanilloid TRPV1).

“In animal models of neuropathic or chronic pain, we found that low doses of CBD administered for seven days alleviate both pain and anxiety, two symptoms often associated,” says the study’s first author Danilo De Gregorio, a postdoctoral fellow at McGill University.

Lead author Gabriella Gobbi sees this as a new advancement for the evidence-based application of cannabis in medicine with CBD likely offering a safe alternative to THC and opioids for chronic pain, such as back pain, sciatica, diabetic, cancer, or post-trauma pain.

“Our findings elucidate the mechanism of action of CBD and show that it can be used as medicine without the dangerous side effects of the THC,” says Gobbi, a professor of psychiatry.

Despite widespread public usage, little clinical studies exist on CBD, which became legal in Canada on October 17, 2018, following the passage of Canada’s Cannabis Act.

Futurity